DUBLIN--(BUSINESS WIRE)--The 'Non-Small Cell Lung Cancer Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis' report has been added to ResearchAndMarkets.com's offering.

都柏林-（商业线）--“非小细胞肺癌市场，规模，全球预测2023-2030，行业趋势，增长，份额，前景，通货膨胀影响，机会公司分析”报告已被添加到ResearchAndMarkets.com的产品。

The Non-Small Cell Lung Cancer (NSCLC) Market is predicted to reach a value of US$ 59.77 billion by the year 2030.

预计到2030年，非小细胞肺癌（NSCLC）市场将达到597.7亿美元。

NSCLC constitutes a group of lung cancers, encompassing subtypes like squamous cell carcinoma and adenocarcinoma. Treatment options for NSCLC include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.

NSCLC构成一组肺癌，包括鳞状细胞癌和腺癌等亚型。NSCLC的治疗选择包括手术，化疗，放射治疗，靶向治疗和免疫治疗。

Accounting for 80%-85% of all lung cancer cases globally, NSCLC has driven key market players to focus on continuous innovation and efficacy enhancement in therapeutics. This prominence is due to lung cancer's status as one of the most common cancers worldwide, contributing to a significant number of global deaths..

NSCLC占全球所有肺癌病例的80%-85%，促使主要市场参与者专注于治疗领域的持续创新和功效提升。这一突出地位是由于肺癌作为全球最常见的癌症之一的地位，导致全球大量死亡。。

The Non-Small Cell Lung Cancer market is expected to exhibit a Compound Annual Growth Rate (CAGR) of 11.64% during the forecast period from 2022 to 2030. T

预计在2022年至2030年的预测期间，非小细胞肺癌市场的复合年增长率（CAGR）为11.64%。T

he increasing number of NSCLC patients globally is a key driver of market growth. Factors such as smoking, tobacco and alcohol consumption, high supplement doses, sedentary lifestyles, and rising air pollution levels contribute to this trend. According to the World Health Organization (WHO) data from February 2022, 2.2 million lung cancer patients were diagnosed in 2020, with NSCLC accounting for approximately 85% of all lung cancer cases.

全球越来越多的NSCLC患者是市场增长的关键驱动力。吸烟，烟酒消费，高补充剂量，久坐不动的生活方式以及空气污染水平上升等因素促成了这一趋势。根据世界卫生组织（WHO）2022年2月的数据，2020年诊断出220万肺癌患者，其中NSCLC约占所有肺癌病例的85%。

This high patient base and the growing number of NSCLC patients have led to a substantial demand for effective treatments..

这种高患者基础和越来越多的NSCLC患者导致对有效治疗的巨大需求。。

The NSCLC market's growth is primarily driven by factors like increased tobacco consumption among younger populations, heightened air pollution, and unhealthy lifestyles. Exposure to air with trace amounts of metals such as asbestos and arsenic is a major cause of adenocarcinoma. Furthermore, the rise in smoking and unhealthy lifestyles contributes significantly to NSCLC cases.

NSCLC市场的增长主要受年轻人群烟草消费增加，空气污染加剧和生活方式不健康等因素驱动。暴露于空气中微量金属如石棉和砷是腺癌的主要原因。此外，吸烟和不健康生活方式的增加对NSCLC病例有显着贡献。

Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are the main subtypes of NSCLC. Among these, adenocarcinoma holds the major market share due to its unique characteristics and genetic profiles..

腺癌，鳞状细胞癌和大细胞癌是NSCLC的主要亚型。其中，腺癌由于其独特的特征和遗传特征而占据了主要的市场份额。。

Chemotherapy is emerging as the fastest-growing revenue segment in the NSCLC market, owing to its effectiveness in targeting rapidly dividing cells and preventing their growth. Ongoing research and development activities by key players are also propelling market growth. Kinase inhibitors dominate the NSCLC market's drug class segment due to their precision in targeting specific molecular pathways driving tumor growth..

化疗正在成为NSCLC市场增长最快的收入领域，因为它有效地瞄准快速分裂的细胞并防止其增长。主要参与者正在进行的研发活动也推动了市场的增长。激酶抑制剂在靶向驱动肿瘤生长的特定分子途径方面具有精确性，因此在NSCLC市场的药物类别领域占据主导地位。。

Specialty hospitals are experiencing rapid growth in the NSCLC treatment realm, catering specifically to the complex needs of lung cancer patients. They provide a conducive environment for diagnostics, targeted therapies, surgical interventions, and post-treatment support.

专科医院在NSCLC治疗领域正在快速发展，专门针对肺癌患者的复杂需求。它们为诊断，靶向治疗，手术干预和治疗后支持提供了有利的环境。

Key Players:

主要参与者：

Bayar Healthcare

医疗保健付款

Eli Lilly

礼来

Biogen Inc.

Biogen股份有限公司。

Merck & Co.

默克公司。

AbbVie Inc.

AbbVie股份有限公司。

AstraZeneca

阿斯利康

Novartis

诺华

Pfizer Inc.

辉瑞公司。

Avid Bioservices, Inc.

Avid Bioservices，股份有限公司。

Blueprint Medicines Company

蓝图药品公司

Astellas Pharma

阿斯特拉制药

Key Attributes:

关键属性：

Report Attribute

报告属性

Details

细节

No. of Pages

页数

240

240

Forecast Period

预测期

2022 - 2030

2022 - 2030

Estimated Market Value (USD) in 2022

2022年的估计市场价值（美元）

$24.77 Billion

247.7亿美元

Forecasted Market Value (USD) by 2030

到2030年预测的市场价值（美元）

$59.77 Billion

597.7亿美元

Compound Annual Growth Rate

年均复合增长率

11.6%

11.6%

Regions Covered

覆盖的区域

Global

全球的

Key Topics Covered:

涵盖的主要主题：

1. Introduction

1.简介

2. Research& Methodology

2.研究与方法

3. Executive Summary

3.执行摘要

4. Market Dynamics

4.市场动态

4.1 Growth Drivers

4.1增长驱动因素

4.2 Challenges

4.2挑战

5. Non-Small Cell Lung Cancer Treatment (NSCLC) Market

5.非小细胞肺癌治疗（NSCLC）市场

6. Market Share - Non-Small Cell Lung Cancer Treatment (NSCLC)

6.市场份额-非小细胞肺癌治疗（NSCLC）

7. Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

7.类型-非小细胞肺癌治疗（NSCLC）市场

8. Treatment - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

8.治疗-非小细胞肺癌治疗（NSCLC）市场

9. Drug Class - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

9.药物类别-非小细胞肺癌治疗（NSCLC）市场

10. End User - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

10.最终用户-非小细胞肺癌治疗（NSCLC）市场

11. Country - Non-Small Cell Lung Cancer Treatment (NSCLC) Market

11.国家-非小细胞肺癌治疗（NSCLC）市场

12. Porters Five Forces - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market

12.Porters五种力量-全球非小细胞肺癌治疗（NSCLC）市场

13. SWOT Analysis - Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market

13.SWOT分析-全球非小细胞肺癌治疗（NSCLC）市场

14. Key Players

14.关键球员

For more information about this report visit https://www.researchandmarkets.com/r/8ai4xu

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/8ai4xu

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是国际市场研究报告和市场数据的全球领先来源。我们为您提供有关国际和区域市场，关键行业，顶级公司，新产品和最新趋势的最新数据。